GlassScriptPhysician profile
Hannah Clevenger
NPI 1225786700
$8,528.25
in general payments reported to CMS, 2019-2025
36 companies · $3,867 in 2025
The $3,867 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $998 · 2023: $2,315 · 2024: $1,349 · 2025: $3,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,431 · Education: $99.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,431.19 |
| Education | $99.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,805.03 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,503.89 | 2022-2025 | |
| Genzyme Corporation | $716.76 | 2022-2025 | |
| Ardelyx, INC. | $578.86 | 2022-2025 | Ibsrela |
| Celgene Corporation | $503.69 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $474.50 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $366.64 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $341.46 | 2022-2025 | |
| Madrigal Pharmaceuticals | $319.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $262.14 | 2023-2025 | Vemlidy |
| Regeneron Healthcare Solutions, INC. | $196.14 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $166.34 | 2023-2025 | Ocaliva |
| Amgen INC. | $162.30 | 2022-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $149.56 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $144.78 | 2025 | Iqirvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $100.37 | 2024-2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $94.89 | 2022 | |
| Janssen Scientific Affairs, LLC | $75.50 | 2023 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $72.89 | 2022-2023 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $70.60 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $69.51 | 2022-2024 | Sucraid |
| Medtronic, INC. | $52.11 | 2025 | Pillcam |
| Redhill Biopharma INC. | $44.16 | 2022 | |
| Nestle Healthcare Nutrition INC. | $38.95 | 2022 | |
| Digestive Care, INC. | $26.98 | 2024 | Pertzye |
| Organon LLC | $23.13 | 2022 | |
| Daiichi Sankyo INC. | $21.10 | 2022 | |
| Ethicon US, LLC | $19.46 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.08 | 2023 | Linzess |
| Intra-Sana Laboratories | $19.06 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Horizon Therapeutics Plc | $18.55 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.07 | 2024 | Givlaari |
| Merck Sharp & Dohme LLC | $14.83 | 2023 | Dificid |
| W. L. Gore & Associates, INC. | $14.40 | 2023 | Gore Cardioform Septal Occluder |
| Fresenius Kabi USA, LLC | $13.40 | 2024 | Idacio |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Clevenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.